Access to regulatory data from the European Medicines Agency: the times they are a-changing
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2046-4053
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Access to regulatory data from the European Medicines Agency: the times they are a-changing ; volume:1 ; number:1 ; day:30 ; month:10 ; year:2012 ; pages:1-4 ; date:12.2012
Systematic Reviews ; 1, Heft 1 (30.10.2012), 1-4, 12.2012
- Creator
-
Wieseler, Beate
- Contributor
- DOI
-
10.1186/2046-4053-1-50
- URN
-
urn:nbn:de:1111-201607116771
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:00 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Wieseler, Beate
- McGauran, Natalie
- Kerekes, Michaela F.
- Kaiser, Thomas
- SpringerLink (Online service)
Other Objects (12)
Establishment of the African Medicines Agency: progress, challenges and regulatory readiness
Is Medicines Parallel Trade "Regulatory Arbitrage'"?
Is medicines parallel trade ‘regulatory arbitrage’?
Regulatory roadmap for nanotechnology based medicines
Names, They Are A-Changing
Comparison of hydroxyethyl starch regulatory summaries from the Food and Drug Administration and the European Medicines Agency
Regulatory Reform Outcomes and Accelerated Regulatory Pathways for New Prescription Medicines in Australia
Agency and changing world views in Africa
Requirements for generic anti-epileptic medicines: a regulatory perspective
Review: UK medicines likely to be affected by the proposed European Medicines Agency’s guidelines on phthalates
Decisions by regulatory agencies: are they evidence-based?
Ocular medicines in children: the regulatory situation related to clinical research
Establishment of the African Medicines Agency: progress, challenges and regulatory readiness
Is Medicines Parallel Trade "Regulatory Arbitrage'"?
Is medicines parallel trade ‘regulatory arbitrage’?
Regulatory roadmap for nanotechnology based medicines
Names, They Are A-Changing
Comparison of hydroxyethyl starch regulatory summaries from the Food and Drug Administration and the European Medicines Agency
Regulatory Reform Outcomes and Accelerated Regulatory Pathways for New Prescription Medicines in Australia
Agency and changing world views in Africa
Requirements for generic anti-epileptic medicines: a regulatory perspective
Review: UK medicines likely to be affected by the proposed European Medicines Agency’s guidelines on phthalates
Decisions by regulatory agencies: are they evidence-based?
Ocular medicines in children: the regulatory situation related to clinical research
Establishment of the African Medicines Agency: progress, challenges and regulatory readiness
Is Medicines Parallel Trade "Regulatory Arbitrage'"?
Is medicines parallel trade ‘regulatory arbitrage’?
Regulatory roadmap for nanotechnology based medicines
Names, They Are A-Changing
Comparison of hydroxyethyl starch regulatory summaries from the Food and Drug Administration and the European Medicines Agency
Regulatory Reform Outcomes and Accelerated Regulatory Pathways for New Prescription Medicines in Australia
Agency and changing world views in Africa
Requirements for generic anti-epileptic medicines: a regulatory perspective
Review: UK medicines likely to be affected by the proposed European Medicines Agency’s guidelines on phthalates
Decisions by regulatory agencies: are they evidence-based?